Where Do Potent P2Y12 Inhibitors Fit Into Current Practice? - Stroke Prevention

Published: 27 February 2023

  • Views:

    Views Icon 9525
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating


This broadcast series 'Where Do Potent P2Y12 Inhibitors Fit Into Current Practice?' will reappraise potent P2Y12 inhibitors, as evidence accumulates to support their broader use. At this juncture, there is still some uncertainty around patient selection, initiation and long-term management.


The fourth, and final, broadcast in this series, focused on Stroke Prevention. In this on-demand version of the live broadcast, Radcliffe Medical Education bring together a global faculty of experts in the field to look at current guidance, the landmark data, gaps in evidence and seek to provide practical guidance.


Prof Clay Johnston (Harbor Health, Texas, US) chairs the proceedings, and is joined by Prof Philippe Gabriel Steg (Hospital Bichat-Claude Bernard, Paris, FR), Dr Shelagh Coutts (University of Calgary, CA) and Prof Jesse Dawson (University of Glasgow, UK) for a series of insightful presentations and discussions.


You can also catch up on previous broadcasts in this series:

This broadcast series is supported by an unrestricted educational grant from AstraZeneca.

Key Learning Objectives

  • Recall recent trial data for antiplatelet therapies in secondary stroke prevention
  • Apply clinical judgement and trial data to develop optimal antiplatelet strategies in noncardioembolic stroke and TIA
  • Use guidance and recent trial data to formulate optimal antiplatelet strategies in large artery atherosclerosis
  • Confidently prescribe potent antiplatelet therapies by balancing ischaemic and bleeding risk

Target Audience

  • Neurologists
  • General Cardiologists
  • Interventional Cardiologists

More from this programme

Part 1

Potent Antiplatelets in Secondary Stroke Prevention: Where Do They Fit In?

Prof Clay Johnston provides an overview of the current guidance around the use of antiplatelet therapy in secondary stroke prevention.

Part 2

Potent P2Y12 Inhibitors in Large Artery Atherosclerosis: Which Patients Benefit?

Dr Shelagh Coutts focuses on large artery atherosclerosis and the clinical evidence behind potent P2Y12 inhibitors in this population.

Part 3

Risk Stratification in Secondary Stroke Prevention

Prof Jesse Dawson discusses the impact of genetics and race on outcomes, assessing the current requirement for genetic testing in specific patients.

Part 4

Balancing Ischaemic and Bleeding Risk: Insights From Cardiology

Prof Philippe Gabriel Steg provides insight into balancing risk through the eyes of a cardiologist.

Part 5

Antiplatelet Strategies in Non-cardioembolic Ischaemic Stroke & TIA

Prof Jesse Dawson and Dr Shelagh Coutts each present a patient. Following this, the panel discuss treatment strategies for both, as well as answering audience questions. 

Faculty Biographies

Jesse Dawson

Jesse Dawson

Professor of Stroke Medicine and Consultant Physician

Prof Jesse Dawson is Professor of Stroke Medicine and Consultant Physician at the Queen Elizabeth University Hospital in Glasgow. His research portfolio includes prevention and rehabilitation clinical trials in stroke survivors, with main interest in improving the long-term outcome after stroke.

Prof Dawson is the NHS Research Scotland lead for stroke research and sits on the editorial board of Stroke.

Prof Dawson was recognised as a Paul Dudley White International Scholar at the International Stroke Conference in February 2022. This was awarded to him and his co-authors for their work on Vagus Nerve Stimulation as a treatment for long-term arm weakness after stroke. Prof Dawson is the primary author of the highest ranked abstract submitted from the UK.

View full profile